<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical guidelines for determining appropriateness of hospice referral: Non-disease-specific baseline guidelines plus comorbidities</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical guidelines for determining appropriateness of hospice referral: Non-disease-specific baseline guidelines plus comorbidities</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medical guidelines for determining appropriateness of hospice referral: Non-disease-specific baseline guidelines plus comorbidities</div><div class="cntnt"><table cellspacing="0"><tbody> <tr class="divider_bottom"> <td> <p>A patient will be considered to have a life expectancy of 6 months or less if they meet the non-disease-specific <strong>"Decline in clinical status"</strong> guidelines described in Part I. Alternatively, the baseline non-disease-specific guidelines described in Part II plus the applicable disease-specific guidelines (listed in a separate table) will establish the necessary expectancy. </p> <p>A patient will be considered to have a life expectancy of 6 months or less if there is documented evidence of decline in clinical status that is not considered to be reversible based on the guidelines below.</p> </td> </tr> <tr> <td class="subtitle1_single">I. Decline in clinical status guidelines</td> </tr> <tr> <td class="indent1">A. Progression of disease as documented by worsening clinical status, symptoms, signs, and laboratory results</td> </tr> <tr> <td class="indent2">Clinical status:</td> </tr> <tr> <td class="indent3">a. Recurrent or intractable serious infections, such as pneumonia, sepsis, or pyelonephritis</td> </tr> <tr> <td class="indent3">b. Progressive inanition as documented by:</td> </tr> <tr> <td class="indent4"> <ol> <li>Weight loss of at least 10% body weight in the prior 6 months, not due to reversible causes (eg, depression or use of diuretics) </li> <li>Decreasing anthropomorphic measurements (mid-arm circumference, abdominal girth), not due to reversible causes (eg, depression or use of diuretics) </li> <li>Observation of ill-fitting clothes, decrease in skin turgor, increasing skin folds, or other observation of weight loss in a patient without a documented weight </li> <li>Decreasing serum albumin or cholesterol </li> <li>Dysphagia leading to recurrent aspiration and/or inadequate oral intake documented by decreasing food portion consumption </li> </ol> </td> </tr> <tr> <td class="indent2">Symptoms:</td> </tr> <tr> <td class="indent3">a. Dyspnea with increasing respiratory rate</td> </tr> <tr> <td class="indent3">b. Cough, intractable</td> </tr> <tr> <td class="indent3">c. Nausea/vomiting poorly responsive to treatment</td> </tr> <tr> <td class="indent3">d. Diarrhea, intractable</td> </tr> <tr> <td class="indent3">e. Pain requiring increasing doses of major analgesics more than briefly</td> </tr> <tr> <td class="indent2">Signs:</td> </tr> <tr> <td class="indent3">a. Decline in systolic blood pressure to below 90 or progressive postural hypotension</td> </tr> <tr> <td class="indent3">b. Ascites</td> </tr> <tr> <td class="indent3">c. Venous, arterial, or lymphatic obstruction due to local progression or metastatic disease</td> </tr> <tr> <td class="indent3">d. Edema</td> </tr> <tr> <td class="indent3">e. Pleural/pericardial effusion</td> </tr> <tr> <td class="indent3">f. Weakness</td> </tr> <tr> <td class="indent3">g. Change in level of consciousness</td> </tr> <tr> <td class="indent2">Laboratory (when available; lab testing is not required to establish hospice eligibility):</td> </tr> <tr> <td class="indent3">a. Increasing pCO<sub>2</sub> or decreasing pO<sub>2</sub> or decreasing SaO<sub>2</sub></td> </tr> <tr> <td class="indent3">b. Increasing calcium, creatinine, or liver function studies</td> </tr> <tr> <td class="indent3">c. Increasing tumor markers (eg, CEA, PSA)</td> </tr> <tr> <td class="indent3">d. Progressively decreasing or increasing serum sodium or increasing serum potassium</td> </tr> <tr> <td class="indent1">B. Decline in KPS or PPS due to progression of disease</td> </tr> <tr> <td class="indent1">C. Progressive decline in FAST for dementia (from 7A on the FAST)</td> </tr> <tr> <td class="indent1">D. Progression to dependence on assistance with additional activities of daily living (refer to Part II, below)</td> </tr> <tr> <td class="indent1">E. Progressive stage 3 to 4 pressure ulcers in spite of optimal care</td> </tr> <tr class="divider_bottom"> <td class="indent1">F. History of increasing emergency department visits, hospitalizations, or clinician visits related to the hospice primary diagnosis prior to election of the hospice benefit</td> </tr> <tr> <td class="subtitle1_single">II. Non-disease-specific baseline guidelines (both A and B should be met) </td> </tr> <tr> <td class="indent1">A. Physiologic impairment of functional status as demonstrated by KPS or PPS &lt;70%. Note that 2 of the disease-specific guidelines (HIV and stroke/coma) establish a lower qualifying KPS or PPS.</td> </tr> <tr> <td class="indent1">B. Dependence on assistance for 2 or more activities of daily living:</td> </tr> <tr> <td class="indent2"> <ol> <li>Feeding </li> <li>Ambulation </li> <li>Continence </li> <li>Transfer </li> <li>Bathing </li> <li>Dressing </li> </ol> </td> </tr> <tr> <td class="indent1"><strong>Comorbidities</strong></td> </tr> <tr> <td class="indent2">Although not the primary hospice diagnosis, the presence of comorbid disease that is likely to contribute to a life expectancy of 6 months or less should be considered for hospice eligibility. Comorbid diseases may include:</td> </tr> <tr> <td class="indent3"> <ol> <li>Chronic obstructive pulmonary disease </li> <li>Congestive heart failure </li> <li>Ischemic heart disease </li> <li>Diabetes mellitus </li> <li>Neurologic disease (CVA, ALS, MS, Parkinson) </li> <li>Renal failure </li> <li>Liver disease </li> <li>Neoplasia </li> <li>Acquired immunodeficiency syndrome (AIDS)/HIV </li> <li>Dementia </li> <li>Refractory severe autoimmune disease (eg, lupus or rheumatoid arthritis) </li> </ol> </td> </tr> <tr> <td class="indent1">A patient will be considered to have a life expectancy of 6 months and be eligible for hospice services if they meet criteria for BOTH the above non-disease-specific baseline guidelines AND disease-specific guidelines (shown on a separate table).</td> </tr> </tbody></table></div><div class="graphic_lgnd">These baseline guidelines do not independently qualify a patient for hospice coverage. Refer to separate table for disease-specific guidelines to be used with these guidelines.</div><div class="graphic_footnotes">pCO<sub>2</sub>: partial pressure of carbon dioxide; pO<sub>2</sub>: partial pressure of oxygen; SaO<sub>2</sub>: arterial oxygen saturation; CEA: carcinoembryonic antigen; PSA: prostate-specific antigen; KPS: Karnofsky Performance Status; PPS: Palliative Performance Score; FAST: Functional Assessment Staging; HIV: human immunodeficiency virus; CVA: cerebrovascular accident or stroke; ALS: amyotrophic lateral sclerosis; MS: multiple sclerosis.</div><div class="graphic_reference">Reproduced from: Centers for Medicare &amp; Medicaid Services. Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L33393) (Accessed on January 18, 2016).</div><div id="graphicVersion">Graphic 87321 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
